Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Riding the M&A rollercoaster

This article was originally published in Scrip

Executive Summary

An important dynamic currently driving the biopharmaceutical space is the replacement of lost product revenue at pharmaceutical companies through merger and acquisition (M&A) transactions biotechs with promising pipelines. However, the hoped for renewal is not always a smooth path and is more often more akin to riding a rollercoaster.

You may also be interested in...



Stockwatch: Can Gilead Wave Its Wand Over Antibody-Drug Conjugates?

After a slow start marked by product withdrawals and toxicity, recent deal-making activity has brought antibody-drug conjugates back from obscurity. But what has changed?

Stockwatch: Is Mallinckrodt Deep Value Pharma?

The pandemic has affected generic pharmaceutical companies more than their branded brethren but accident-prone Mallinckrodt has been hit harder than most.

Stockwatch: Winlevi And Aimmune Excitement Will Be Short-Lived

Apparently positive news for two unglamorous indications – acne and allergy – should be balanced against restrictive reimbursement and market fragmentation.

Topics

Related Companies

UsernamePublicRestriction

Register

PS142351

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel